Cancer gene therapy
Cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression, and spread of cancer. Many cancer therapies have been approved by the Food and Drug Administration to treat specific types of cancer. The development of targeted therapies requires the identification of good targets that is, targets that play a key role in cancer cell growth and survival. One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival.
Related Conference of Cancer gene therapy
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
19th International Conference on Human Genomics and Genomic Medicine
17th International Conference on Human Genetics and Genetic Diseases
Cancer gene therapy Conference Speakers
Recommended Sessions
- Genetically inherited diseases
- Viral gene therapy
- Advanced gene therapy
- Cancer gene therapy
- Cancer Gene Therapy
- Cell & Gene Therapy Products
- Cell and Gene therapy products
- Cell Culture & Bioprocessing
- Cell Science & Stem Cell Research
- Cell Therapy
- Cell Therapy in Pulmonology:
- Cellular therapy
- Clinical trials in cell and gene therapy
- Diabetes Gene Therapy
- Gene therapy
- Gene Therapy Commercialization
- Genomics
- HIV gene therapy
- Regulatory & Safety Aspects of Cell & Gene Therapy
- Skin cell therapy
- Vectors for Gene Therapy
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2026 (UAE)
- Adult Stem Cells and Tissue-Specific Regeneration - Regenerative Medicine_2026 (France)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer and stem cells - CRISPR 2026 (UAE)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cardiovascular Regeneration and Stem Cell Therapeutics - Regenerative Medicine_2026 (France)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- CRISPR technologies and society - CRISPR 2026 (UAE)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2026 (UAE)
- Embryonic Stem Cells and Pluripotent Stem Cells - Regenerative Medicine_2026 (France)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Genome editing and gene regulation in human health - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2026 (UAE)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2026 (UAE)
- Genome Editing Methods and Novel Tools - CRISPR 2026 (UAE)
- Hematopoietic Stem Cell Transplantation - Regenerative Medicine_2026 (France)
- Horizons of CRISPR biology - CRISPR 2026 (UAE)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) - Regenerative Medicine_2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells: Biology and Therapeutic Applications - Regenerative Medicine_2026 (France)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Orthopedic Regenerative Medicine and Bone Tissue Engineering - Regenerative Medicine_2026 (France)
- Plant and Animal Biotechnology - CRISPR 2026 (UAE)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regenerative Medicine: Current Advances and Future Perspectives - Regenerative Medicine_2026 (France)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Regenerative Medicine_2026 (France)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cell Therapy for Neurological Disorders - Regenerative Medicine_2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Biology and Bioinformatics - CRISPR 2026 (UAE)
- Therapeutic Genome Editing - CRISPR 2026 (UAE)

